Cosmo Pharmaceuticals combines accelerating recurring AI and dermatology revenues with a debt-free balance sheet and substantial clascoterone-driven asymmetric upside.
Overview
Cosmo Pharmaceuticals is a clinically oriented life sciences platform spanning optimized GI therapeutics, targeted dermatology, MedTech AI and CDMO manufacturing. Rather than building a costly global sales force, it uses Medtronic, Sun Pharma, Glenmark and InfectoPharm to commercialize products while earning manufacturing revenue, royalties and milestones. **The business is shifting from volatile licensing payments toward recurring revenue:** recurring sales reached €88.1 million in FY2025, 85% of total revenue and up 15.1% year over year. GI Genius recurring revenue rose 211% to €17.9 million, while Winlevi revenue increased 27% to €17.2 million. The principal upside catalyst is clascoterone 5% for male pattern baldness, which delivered a 2.39-fold relative improvement in target-area hair count after 12 months with placebo-comparable safety; US and EU submissions are planned for 2027. FY2025 revenue was €104.2 million and EBITDA €9.52 million, despite the disappearance of large one-off milestones. With zero debt, €128.3 million of cash and investments, and a proposed €2.10 dividend, Cosmo has substantial funding flexibility. At CHF 63.40, consensus targets of CHF 129.49–131.38 and a clascoterone rNPV of CHF 167 indicate substantial potential upside, although execution and regulatory risks remain material.